Modality
Nanobody
MOA
RAS(ON)i
Target
LAG-3
Pathway
Checkpoint
PompeFTDDLBCL
Development Pipeline
Preclinical
~May 2018
→ ~Aug 2019
Phase 1
Nov 2019
→ Nov 2030
Phase 1Current
NCT03379686
987 pts·FTD
2019-11→2030-11·Terminated
NCT07214692
105 pts·Pompe
2023-02→2025-08·Recruiting
1,092 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-08-167mo agoPh2 Data· Pompe
2026-08-235mo awayPh1 Dose Esc· Pompe
2030-11-184.6y awayPh2 Data· FTD
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Termina…
P1/2
Recruit…
Catalysts
Ph2 Data
2025-08-16 · 7mo ago
Pompe
Ph1 Dose Esc
2026-08-23 · 5mo away
Pompe
Ph2 Data
2030-11-18 · 4.6y away
FTD
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03379686 | Phase 1/2 | FTD | Terminated | 987 | SRI-4 |
| NCT07214692 | Phase 1/2 | Pompe | Recruiting | 105 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| 180-3597 | Innovent Bio | Preclinical | SHP2 |